SG11202006782YA - Topical formulations comprising tofacitinib - Google Patents
Topical formulations comprising tofacitinibInfo
- Publication number
- SG11202006782YA SG11202006782YA SG11202006782YA SG11202006782YA SG11202006782YA SG 11202006782Y A SG11202006782Y A SG 11202006782YA SG 11202006782Y A SG11202006782Y A SG 11202006782YA SG 11202006782Y A SG11202006782Y A SG 11202006782YA SG 11202006782Y A SG11202006782Y A SG 11202006782YA
- Authority
- SG
- Singapore
- Prior art keywords
- tofacitinib
- topical formulations
- topical
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624567P | 2018-01-31 | 2018-01-31 | |
| PCT/US2019/014524 WO2019152232A1 (en) | 2018-01-31 | 2019-01-22 | Topical formulations comprising tofacitinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006782YA true SG11202006782YA (en) | 2020-08-28 |
Family
ID=67393025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006782YA SG11202006782YA (en) | 2018-01-31 | 2019-01-22 | Topical formulations comprising tofacitinib |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10960006B2 (pt) |
| EP (1) | EP3746086A4 (pt) |
| JP (1) | JP7324210B2 (pt) |
| KR (1) | KR20200128657A (pt) |
| CN (1) | CN111670036A (pt) |
| AU (1) | AU2019213835A1 (pt) |
| BR (1) | BR112020015688A8 (pt) |
| CA (1) | CA3089108A1 (pt) |
| SG (1) | SG11202006782YA (pt) |
| TW (1) | TW201940174A (pt) |
| WO (1) | WO2019152232A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200128657A (ko) * | 2018-01-31 | 2020-11-16 | 티더블유아이 파머수티컬스, 인코포레이티드 | 토파시티닙을 포함하는 국소 제형 |
| US20210212931A1 (en) * | 2018-01-31 | 2021-07-15 | Twi Pharmaceuticals, Inc. | Topical formulations comprising tofacitinib |
| CA3102395A1 (en) * | 2018-06-04 | 2019-12-12 | Chemistryrx. | Topical compositions for stimulating hair growth |
| US20190381046A1 (en) * | 2018-06-14 | 2019-12-19 | Andrew HANNA | Tofacitinib and baclofen compositions and applications |
| US20200009077A1 (en) * | 2018-07-03 | 2020-01-09 | TRUETIVA, Inc. | Compositions for treating dermatological diseases |
| CA3157594A1 (en) * | 2019-11-08 | 2021-05-14 | Nitin JOSHI | Topical delivery of tofacitinib using ionic liquid |
| US11766438B2 (en) * | 2020-04-24 | 2023-09-26 | Slayback Pharma Llc | Pharmaceutical compositions of tofacitinib for oral administration |
| CN113712919A (zh) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | 治疗秃发脱发的枸橼酸托法替布喷雾剂的制备 |
| WO2022022434A1 (zh) * | 2020-07-27 | 2022-02-03 | 杭州和正医药有限公司 | 含托法替尼药学上可接受的盐的药物组合物、制剂及应用 |
| CN111728953B (zh) * | 2020-07-29 | 2023-08-08 | 中国科学院上海药物研究所 | 一种托法替布或其盐的缓释制剂及其制备方法 |
| CN112402615A (zh) * | 2020-11-11 | 2021-02-26 | 长沙晶易医药科技有限公司 | 一种用于治疗斑秃的复方外用制剂及其制备方法 |
| US20220233544A1 (en) * | 2021-01-28 | 2022-07-28 | Chemistryrx | Treatments for skin conditions |
| CN113730335B (zh) * | 2021-09-18 | 2023-07-28 | 中国药科大学 | 一种托法替布外用药物组合物及其应用 |
| WO2023143345A1 (zh) * | 2022-01-25 | 2023-08-03 | 杭州和正医药有限公司 | 一种含托法替尼的局部用药的药物组合物、制剂及应用 |
| CN116942602B (zh) * | 2023-09-20 | 2023-12-22 | 北京普祺医药科技股份有限公司 | 一种枸橼酸托法替布药物组合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| KR20120115413A (ko) | 2007-07-11 | 2012-10-17 | 화이자 인코포레이티드 | 안구 건조증 치료용 약학 조성물 및 방법 |
| US9198911B2 (en) * | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| WO2012099968A1 (en) * | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating skin cancer associated diseases |
| WO2012135338A1 (en) * | 2011-03-28 | 2012-10-04 | Ratiopharm Gmbh | Processes for preparing tofacitinib salts |
| RU2013144975A (ru) | 2011-04-08 | 2015-05-20 | Пфайзер Инк. | Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения |
| WO2014013014A1 (en) * | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| CN105188758A (zh) * | 2013-03-15 | 2015-12-23 | 梅迪奇斯医药公司 | 氟尼缩松的局部组合物及治疗方法 |
| MX366728B (es) * | 2013-06-24 | 2019-07-22 | Menlo Therapeutics Inc | Uso de serlopitant como antagonistas del receptor nk-1 en prurito. |
| AU2014323131B2 (en) * | 2013-09-18 | 2018-08-09 | Bcn Peptides S.A. | Cortistatin analogues for the treatment of inflammatory and/or immune diseases |
| EP3718558A1 (en) * | 2013-10-08 | 2020-10-07 | Promedior, Inc. | Methods for treating fibrotic cancers |
| KR102530900B1 (ko) * | 2014-03-31 | 2023-05-12 | 암젠 케이-에이, 인크. | 손발톱 및 두피 건선의 치료 방법 |
| US10092541B2 (en) * | 2014-08-15 | 2018-10-09 | Celgene Corporation | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
| MX2017014253A (es) | 2015-05-07 | 2018-04-20 | Univ Columbia | Metodos y composiciones para promover el crecimiento del cabello. |
| WO2017119928A1 (en) | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long acting injectable formulations |
| KR20200128657A (ko) * | 2018-01-31 | 2020-11-16 | 티더블유아이 파머수티컬스, 인코포레이티드 | 토파시티닙을 포함하는 국소 제형 |
| CN108640921B (zh) * | 2018-04-03 | 2022-07-08 | 科兴生物制药股份有限公司 | 一种枸橼酸托法替布的制备方法 |
| US11633399B2 (en) * | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| KR20200082006A (ko) * | 2018-12-28 | 2020-07-08 | 주식회사 대웅제약 | 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법 |
| US20230037905A1 (en) * | 2019-12-31 | 2023-02-09 | Vyne Therapeutics Inc. | Topical composition comprising tofacitinib and fingolimod |
-
2019
- 2019-01-22 KR KR1020207022431A patent/KR20200128657A/ko active Search and Examination
- 2019-01-22 AU AU2019213835A patent/AU2019213835A1/en active Pending
- 2019-01-22 CN CN201980011294.9A patent/CN111670036A/zh active Pending
- 2019-01-22 SG SG11202006782YA patent/SG11202006782YA/en unknown
- 2019-01-22 EP EP19747905.8A patent/EP3746086A4/en active Pending
- 2019-01-22 CA CA3089108A patent/CA3089108A1/en active Pending
- 2019-01-22 JP JP2020541671A patent/JP7324210B2/ja active Active
- 2019-01-22 BR BR112020015688A patent/BR112020015688A8/pt unknown
- 2019-01-22 WO PCT/US2019/014524 patent/WO2019152232A1/en unknown
- 2019-01-22 US US16/254,076 patent/US10960006B2/en active Active
- 2019-01-29 TW TW108103324A patent/TW201940174A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3746086A1 (en) | 2020-12-09 |
| TW201940174A (zh) | 2019-10-16 |
| EP3746086A4 (en) | 2021-10-20 |
| JP7324210B2 (ja) | 2023-08-09 |
| WO2019152232A1 (en) | 2019-08-08 |
| JP2021512096A (ja) | 2021-05-13 |
| BR112020015688A8 (pt) | 2022-07-05 |
| BR112020015688A2 (pt) | 2020-12-08 |
| AU2019213835A1 (en) | 2020-08-06 |
| US20190231782A1 (en) | 2019-08-01 |
| US10960006B2 (en) | 2021-03-30 |
| KR20200128657A (ko) | 2020-11-16 |
| CN111670036A (zh) | 2020-09-15 |
| CA3089108A1 (en) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202006782YA (en) | Topical formulations comprising tofacitinib | |
| SG11202011761XA (en) | Nicotine formulation | |
| EP3328353A4 (en) | TOPICAL SKIN FORMULATIONS | |
| EP3735258A4 (en) | TOPICAL SKIN CARE COMPOSITIONS | |
| EP3324925A4 (en) | TOPICAL SKIN FORMULATIONS | |
| IL266448A (en) | Topical datumidine formulations | |
| IL279284A (en) | Topical detomidine formulations | |
| GB2549418B (en) | Topical formulations comprising dimethicone macromers | |
| GB2586731B (en) | Topical skin care compositions | |
| IL280533A (en) | Topical preparation | |
| IL287416A (en) | Local formulation | |
| GB201904338D0 (en) | Fluorouracil-containing formulations | |
| EP3328354A4 (en) | TOPICAL SKIN FORMULATIONS | |
| PT4045038T (pt) | Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida | |
| IL277213A (en) | Topical preparation | |
| EP3383912A4 (en) | TOPICAL FORMULATIONS | |
| IL290356A (en) | Formulations for Resotide | |
| IL284691A (en) | formulations | |
| PL3856128T3 (pl) | Formulacja filtra przeciwsłonecznego do stosowania miejscowego | |
| SG11202012165WA (en) | Formulations/compositions comprising ibrutinib | |
| IL284072A (en) | local preparations | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB201819028D0 (en) | Butanol-based formulations | |
| ZA202103782B (en) | Teriflunomide topical pharmaceutical compositions | |
| GB201911063D0 (en) | Formulations |